- Home
- RENB vs MNOV Comparison
RENB vs MNOV Comparison
Compare RENB & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- MNOV
- Stock Information
- Founded
- RENB 2011
- MNOV 2000
- Country
- RENB United States
- MNOV United States
- Employees
- RENB N/A
- MNOV N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- MNOV Health Care
- Exchange
- RENB Nasdaq
- MNOV Nasdaq
- Market Cap
- RENB 73.5M
- MNOV 68.2M
- IPO Year
- RENB N/A
- MNOV 2005
- Fundamental
- Price
- RENB $0.31
- MNOV $1.46
- Analyst Decision
- RENB
- MNOV Strong Buy
- Analyst Count
- RENB 0
- MNOV 2
- Target Price
- RENB N/A
- MNOV $7.00
- AVG Volume (30 Days)
- RENB 1.8M
- MNOV 37.1K
- Earning Date
- RENB 05-15-2025
- MNOV 08-07-2025
- Dividend Yield
- RENB N/A
- MNOV N/A
- EPS Growth
- RENB N/A
- MNOV N/A
- EPS
- RENB N/A
- MNOV N/A
- Revenue
- RENB N/A
- MNOV N/A
- Revenue This Year
- RENB N/A
- MNOV N/A
- Revenue Next Year
- RENB N/A
- MNOV N/A
- P/E Ratio
- RENB N/A
- MNOV N/A
- Revenue Growth
- RENB N/A
- MNOV N/A
- 52 Week Low
- RENB $0.26
- MNOV $1.12
- 52 Week High
- RENB $2.10
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- RENB 48.33
- MNOV 69.17
- Support Level
- RENB $0.30
- MNOV $1.24
- Resistance Level
- RENB $0.35
- MNOV $1.38
- Average True Range (ATR)
- RENB 0.03
- MNOV 0.05
- MACD
- RENB 0.00
- MNOV 0.02
- Stochastic Oscillator
- RENB 46.77
- MNOV 100.00
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.